Home Neoplasma 2026 Neoplasma Vol.73, 2026, No.1, p. 1–9

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.73, 2026, No.1, p. 1–9

Title: Stem cells derived suicide gene exosomes: a promising platform for innovative cancer therapy
Author: Dajana Vanova, Michal Andrezal, Ursula Altanerova, Miroslava Matuskova, Cestmir Altaner

Abstract: Innovative cancer treatments are needed for metastatic tumors that currently do not have adequate therapies. This review highlights recent progress in suicide gene small extracellular vesicles, particularly exosomes as a new form of intracellular anti-cancer drug. Suicide gene exosomes are produced by tumor-targeting human mesenchymal stem cells that have been genetically modified to express the yeast cytosine deaminase::uracil phosphoribosyl transferase fused gene (yCD::UPRT) along with the prodrug 5-fluorocytosine (5-FC). The yCD::UPRT-MSC-secretome containing  tumor targeted exosomes, convert 5-FC into the cytotoxic compound 5-fluorouracil (5-FU) and its metabolites within the tumor environment. The second popular system we are investigating involves the suicide gene exosomes derived from thymidine kinase of Herpes Simplex Virus in conjunction with a prodrug ganciclovir. Extracellular vesicles secreted by tumor associated cells contribute to tumor growth and metastasis. When these cells are transduced with yCD::UPRT suicide gene, they can act as a source of therapeutic exosomes capable of intracellularly converting nontoxic prodrug 5-FC to a cytotoxic 5-FU. Combined action of suicide gene exosomes from MSCs and cancer associated fibroblasts (CAFs) is a promising platform for aggressive tumors treatment. Furthermore, suicide gene exosomes can be enhanced with additional anti-cancer drugs and customized for targeted delivery. In this review, we trace the history of these findings, present therapeutic outcomes from in vitro and in vivo studies, and explore the future potential of therapeutically beneficial exosomes for cancer treatment.

Keywords: gene-directed enzyme prodrug therapy, mesenchymal stem/stromal cells, suicide gene exosomes, cancer associated fibroblasts
Year: 2026, Volume: 73, Issue: 1 Page From: 1, Page To: 9
doi:10.4149/neo_2025_251119N487


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.